pycoa play, page-6

Hi DS, great post, i didnt know that about our CEO and PYC. Thats very very interesting. I might have to slip that question in next time i talk to him!

Been having a look at it for some time now myself and am quite attracted to their low cost business model and high margin profits.

You make a good point about the cashburn of both companies but PYC's market cap is less then 1/2 that of our other company and with money hitting the bank for a positive cashflow quarter last quarter and expected revenues to increase this quarter i think PYC may easily catch up to the $50-$60 million market cap in the near future.

Seems that the cash payments to be made and being made to PYC will help them turn over some serious revenue numbers in the future.

By memory one of our signed partners is coming up to the stage (late June) where they will have to make a decision under the current contract in regards to using PYC's peptides which could bank them some very large revenues.

I have started to slowly accumulate and will do so as money becomes avalibale.

The current market cap seems quite small for a company with signed deals with 4 of the TOP 10 big pharmas with more said to be signed off by June 30, a cashflow positive business (although it needs to be back up quarter on quarter), $4 million in the bank and a technology that only PYC has access to and no one else allowed to go near it which not only makes them unique, game changing, take over material but gives them the edge over the reat as there is no other competition.

If companies want to create new drugs etc they will be needing PYC's peptides to assist them.

Although as DS points out cash burn his higher then our other little gem when you look at other BIO's with no cash, no revenue, higher market caps and higher cash burn it doesnt look to bad at all.

As long as management can keep meeting customers requirements which they have we will see a gradual rise in amrket cap as the company turns the balance sheet into quater on quarter profits.

The upside vs the downside, the sercurity of the cash at bank, big name partners, large milestone payments and in an area that they have the technolgy all to themself its deffentaly worth my money as an investment. The cashflow positive last 1/4 is also a major milestone in itself and now all we need to see is this continue.